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Abstract
Background and Aims: Inflammatory bowel disease (IBD) is a chronic disease affecting mainly young
people in their reproductive years. IBD therefore has a major impact on patients’ family planning
decisions. Management of IBD in pregnancy requires a challenging balance between optimal disease
control and drug safety considerations.
This article aims to provide a framework for clinical decision making in IBD based on review of
the literature on pregnancy-related topics.
Methods: Medline searches with search terms ‘IBD’, ‘Crohn's disease’ or ‘ulcerative colitis’ in
combination with keywords for the topics fertility, pregnancy, congenital abnormalities and drugs
names of drugs used for treatment of IBD.
Results: IBD patients have normal fertility, except for women after ileal pouch-anal
anastomosis (IPAA) and men under sulfasalazine treatment. Achieving and maintaining disease
remission is a key factor for successful pregnancy outcomes in this population, as active disease
at conception carries an increased risk of preterm delivery and low birth weight.rine; 6-TGN, 6-thioguaninenucleotides; AZA, azathioprine; BCG, Bacillus Calmette Guerin; IPAA, ileal
rexate.
ent of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.
uzleuven.be (S. Vermeire).
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812 S. Vermeire et al.Clinicians should discuss the need for drug therapy to maintain remission with their
patients in order to ensure therapy compliance. Most IBD drugs are compatible with
pregnancy, except for methotrexate and thalidomide. If possible, anti-TNF therapy should
be stopped by the end of the second trimester and the choice of delivery route should be
discussed with the patient.
Conclusions: Disease control prior to conception and throughout pregnancy is the cornerstone of
successful pregnancy management in IBD patients.
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As a chronic disease affecting mainly young people in their
reproductive years, inflammatory bowel disease (IBD) has a
major impact on patients’ family planning decisions. When
active disease is under control, clinicians need to take time
to counsel IBD patients on topics such as fertility, pregnancy,
and genetic aspects of IBD. Patients wishing to become
pregnant need to be informed on pregnancy outcomes and
therapeutic options in the preconception period and during
pregnancy.
This article aims to summarize the current knowledge
about the effect of IBD on fertility, the disease course of IBD
during pregnancy, as well as pregnancy outcomes and drug
treatment of IBD during pregnancy and lactation, to provide
clinicians with a framework to guide their care of IBD
patients in these challenging circumstances.2. Effect of IBD on fertility
In Crohn's disease (CD), fertility is observed to be normal1–3
or slightly reduced.4 Subfertility is mainly reported in CD
patients with active disease.5
In ulcerative colitis (UC) overall fertility rates are
normal,6,7 except after surgical resection with ileal pouch-
anal anastomosis (IPAA).8–11 A meta-analysis estimated the
risk of infertility after IPAA to be increased by a factor
three.12 Colectomy with ileorectal anastomosis13 or subtotal
colectomy with an ileostomy and pouch creation after
childbearing14 may be reasonable alternatives for women
wishing to become pregnant, as subfertility or infertility
after IPAA is mainly attributed to postsurgical adhesions in
the pelvic region with subsequent fallopian tube occlu-
sion.14,15 Laparoscopic IPAA could reduce adhesions and may
be a suitable alternative for patients of child-bearing age.16
813Management of inflammatory bowel disease in pregnancyMen with IBD can experience reduced fertility or infertility
when treated with sulfasalazine. This drug is known to cause
reversible semen abnormalities (oligospermia, reduced motil-
ity, abnormal morphology) and infertility in up to 60% of
men.17–20 Themechanism by which sulfasalazine induces male
fertility is not well known, but impaired spermmaturation and
oxidative stress are thought to play a role.21,22 Sperm quality is
restored twomonths after sulfasalazine withdrawal. Switching
to mesalazine also restores male fertility, indicating that the
sulfapyridine component is the culprit in sulfasalazine-induced
infertility.20
Azathioprine does not impair male fertility,23 but its
teratogenic potential, mainly attributed to its metabolite 6-
mercaptopurine (6-MP), remains controversial. Two studies
have reported an increased incidence in congenital mal-
formations in children fathered by IBD patients on thiopur-
ines,24,25 whereas two other studies did not observe a
significant effect of preconceptive thiopurine exposure of
the father on pregnancy outcomes.26,27
Infliximab has been reported to increase semen volume
with a trend towards decreased sperm motility. How these
findings impact the fertility of men treated with infliximab is
not known yet.28 Potentially infliximab may also serve to
counter the negative effects of TNF-α on sperm quality.29
Data on the impact of other biologicals on male fertility are
currently lacking.
Although fecundity in IBD patients is normal, except for
women with a history of IPAA and men taking sulfasalazine,
studies consistently find lower birth rates and smaller family
sizes in IBD patients, as compared to the general population.
This ‘voluntary childlessness’ was observed for both female
and male IBD patients,30 and illustrates the important impact
of IBD on family planning. In a survey among 255 Australian IBD
patients fear concerning IBD heritability, risk of congenital
anomalies and medication teratogenicity were reported as
factors contributing to decreased family size. Fear of infertility
was reported by 42.7% of patients, although fertility rates and
use of medical fertility advice among study participants were
comparable to the normal Australian population.31
3. Effect of pregnancy on IBD disease activity
3.1. Disease activity during pregnancy
A retrospective study including 70 pregnancies in 61 patients
with Crohn's disease observed a small but significant
decrease in the Harvey-Bradshaw index of disease activity
during pregnancy in comparison with the year preceding and
following the pregnancy.32 In this study, the reduced disease
activity in pregnancy was partly due to reduced tobacco
smoking during pregnancy. Smoking has a known negative
effect on the course of Crohn's disease.33
A large European prospective study observed that 74% of
CD and 67% of UC patients with active disease at conception
achieved remission later during pregnancy.34
3.2. Risk of flare: comparable to that in
non-pregnant patients
Clinical experience corroborates the early observations of
Khosla et al.1 that patients with active disease atconception, often continue to have symptoms during
pregnancy, whereas a normal course of pregnancy can be
expected in patients who conceive when in remission. In the
literature, CD flare rates during pregnancy of 14–34% are
reported, similar to that in non-pregnant patients.7,34,35 A
European cohort study with a 10-year follow-up period
observed that if conception occurred during remission, flare
rates were comparable to those in non-pregnant patients
with IBD, whereas two-thirds of patients relapsed during
pregnancy when conception occurred during a period of
active disease. Of these, two-thirds will experience further
deterioration.5 In a study including 35 pregnancies in 23
women over a 12 year period, a 26% exacerbation rate
during pregnancy was found, which is similar to that in the
Crohn patient population at large.36 A Danish study reported
40.3% of relapses during pregnancy in UC, as compared to
13.6% in the 6 months prior to pregnancy.37
Exacerbations of disease, particularly in the first trimes-
ter of pregnancy are often due to discontinuation of
maintenance therapy.38
3.3. Lower risk of IBD relapse and complications
after pregnancy
Whether disease flares are more likely to occur in the
postpartum period remains controversial, but pregnancy
seems to have a beneficial effect on the disease course of
IBD. A small prospective study reported a decrease in relapse
rate in CD as well as UC patients four years after pregnancy,
in comparison with the 3 years before pregnancy.39 Similar
findings were reported in a large European cohort study,
where yearly flare rates decreased from 0.34 to 0.18 in UC
and from 0.76 to 0.12 in CD. Pregnancy did not influence the
incidence of stenosis or resection rates in this cohort.5
Earlier studies reported reduced stenosis and resection
rates in women with IBD after pregnancy.40,41 The potential
mechanism for reduced complication rate of IBD after
pregnancy remains elusive, but the hormone relaxin, the
effect of pregnancy on the immune response, as well as
foetomaternal HLA disparity have all been mentioned as
potential explanations.41,42
A retrospective study by Kane et al. observed that 43% of
IBD patients who breastfed their infants experienced a
postpartum disease flare, but after adjustment for medica-
tion cessation, the risk of postpartum flare in breastfeeding
IBD mothers was not significant, indicating that discontinu-
ation of therapy while breastfeeding was the main determi-
nant of the high flare rate in this study.43 A 2009 registry
study on the other hand, found comparable postpartum flare
rates in breastfeeding (26%, OR 0.58, 95% CI 0.24–1.43)
versus not breastfeeding (29.4%) IBD mothers44
4. Effect of IBD on pregnancy outcome
Current evidence indicates that quiescent disease has
minimal impact on the course and outcome of pregnancy in
IBD patients, whereas patients with active disease at
conception have increased rates of spontaneous abortion1,36
and a significantly increased risk of preterm delivery and low
birth weight.35,45,46 Preterm delivery is further associated
with disease flares during pregnancy.36,47
814 S. Vermeire et al.A recent European prospective study including 332
pregnant women with IBD from 68 centers in 12 countries
concluded that overall pregnancy outcomes for women with
CD or UC did not differ significantly from those in pregnant
patients without IBD.34
A meta-analysis covering 12 studies in 3907 women with
IBD found an increased odds ratio for premature delivery in
IBD patients (OR 1.87, 95% CI 1.52–2.31), comparable in CD
and UC. This study also described an elevated risk for low
birth weight in CD (OR 2.82, 95% CI 1.42–5.60) but not in UC
and a significant increase in congenital abnormalities (OR
2.37, 95% CI 1.47–3.82). The observed increased risk of
congenital malformations was mainly observed in UC (OR
3.88, 95% CI 1.14–10.67), whereas the risk in CD was not
significantly increased (OR 2.14, 95% CI 0.97–4.74).48
A study including newborns from 510 Crohn patients from
6 national registries and 3018 controls observed a signifi-
cant, albeit modest decrease in birth weight, with babies of
primiparous versus multiparous CD patients weighing on
average 142 g and 105 g less than those of controls after
adjustment for confounding factors.49 A Swedish population
study found 4.5% and 1.2% of children born to IBD patients
had low and very low birth weight, as compared to 2.9% and
0.6% in the overall Swedish population. Neonates of Swedish
IBD patients were small for gestational age in 4.0% of cases,
against 2.9% overall.50 Moser et al. additionally found an
increased incidence of poor maternal weight gain during
pregnancy in CD patients with quiescent disease at
conception.35
Retrospective analysis of 502 pregnancies before and 121
pregnancies after diagnosis of IBD observed an increased risk
of low birth weight in IBD of both groups,51 indicating that
IBD has an influence on pregnancy, even in the preclinical
phase. Birth weight in babies born to CD patients was
significantly lower than that of UC offspring in this study,
corroborating the earlier study by Dominitz et al., who
reported increased risk for preterm delivery, low birth
weight and small for gestational age births in CD but not in
UC.52
The risk of congenital malformations may be slightly
increased in children of IBD patients, mainly for patients
with UC,48 although a number of studies did not observe an
increased risk of congenital abnormalities.5,53 A population-
based case control study in Hungary found no overall
increased risk of congenital anomalies in offspring of UC
patients (OR 1.3 (95% CI 0.9–1.8), but did observe elevated
risks for the presence of limb deficiencies (OR 6.2, 95% CI
2.9–13.1), obstructive urinary anomalies (OR 3.3, 95% CI
1.1–9.5) and multiple congenital anomalies (OR 2.6, 95% CI
1.3–5.4) in children of UC mothers. Maternal UC was not
associated with cleft palate or cardiovascular defects in this
study.54 A retrospective cohort study in Washington state
reported congenital malformations in 7.9% of UC births (OR
3.8, 95% CI 1.5–9.8) versus 3.4% in CD and 1.7% in controls.52
Another case–control study found congenital abnormalities
in 5.5% of births in IBD pregnancies, but no difference
between CD and UC.51 The reported risks of congenital
anomalies in UC are quite low and do not justify discouraging
women with UC from becoming pregnant. Attentive prenatal
monitoring is warranted, however.
Pregnancies in both CD (20.9% of cesarean sections) and
UC patients (20.8%) ended more often with cesarean sectionin comparison with the general population (15%).55 A more
recent Californian cohort study found borderline differences
in cesarean section rate between IBD patients and controls
(13.5% versus 9.5%, p=0.05),56 whereas a 2009 population-
based study found that pregnancies of patients who needed
to be hospitalized had a higher risk of ending in cesarean
section for CD (OR 1.72; 95% CI 1.44–2.04) as well as UC
patients (OR 1.29; 95% CI, 1.01–1.66), in comparison with
patients without IBD.57
Active perianal disease at the time of delivery is an
indication for cesarean section, whereas cesarean section
without history of perianal disease or inactive perianal
disease do not require a cesarean section.55 In UC patients
with IPAA cesarean section rates of almost 50% were
reported, but the incidence of pouch-related complications
was low and pouch function was found to be unrelated to the
mode of delivery.58 However, the most recent ECCO
guidelines state that the presence of an ileoanal pouch in
CD patients is an indication for caesarean section.59
5. Drug treatment of IBD during preconception,
pregnancy and lactation
Most of the drugs used in the treatment of IBD are not
associated with increased risk of congenital anomalies or
adverse effects on the fetus and are thus compatible with
pregnancy. Moskovitz et al. studied 207 conceptions in 113
IBD patients and found no evidence of an influence of drug
treatment on pregnancy outcome.60
The 2010 ECCO guidelines state that ‘medical treatment
for Crohn's disease (except methotrexate) should generally
continue during pregnancy, because the benefits outweigh
the risks of medication’.59 Moreover, as complications and
adverse pregnancy outcomes mainly occur in patients with
active disease, the main concern should be to achieve
remission prior to conception and maintain quiescent
disease during pregnancy.
Table 2 provides an overview of IBD drugs and the risk
associated with their use during pregnancy and lactation.
Population-based studies in Denmark reported adherence
to medical treatment in 72% of CD and 60% of UC patients
prior to or during pregnancy. Fear of a negative effect on
fertility or the fetus was stated as the main reason for non-
compliance.37,61 UC Patients who received counseling
regarding medical treatment during preconception and
pregnancy were more likely to remain compliant,37 illus-
trating the important role of the clinician in informing IBD
patients accurately on the benefits and risk of drug
treatment prior to conception and during pregnancy.
5.1. Aminosalicylates
It is generally regarded as safe to keep using aminosalicy-
lates during pregnancy (FDA category B drug), despite some
reports noting a higher incidence of neural tube defects, oral
cleft, and cardiovascular defects.62
A number of studies concluded that sulfasalazine use
during pregnancy does not give rise to increased rates of
birth defects in women with IBD, when compared with
untreated IBD patients or the general population.60,63 In a
recent meta-analysis treatment of IBD patients with 5-ASA
Table 1 US Food and Drug Administration categories for drug safety during pregnancy.134
FDA category Description
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus during the first
trimester of pregnancy (and there is no evidence of risk in later trimesters).
B animal reproduction studies have not demonstrated a fetal risk but there are there are no adequate and
well-controlled studies in pregnant women
Or
animal reproduction studies have shown an adverse effect, but adequate and well-controlled studies in
pregnant women have failed to demonstrate a risk to the fetus during the first trimester of pregnancy (and
there is no evidence of a risk in later trimesters)
C Animal reproduction studies have shown an adverse effect on the fetus, there are no adequate and well-
controlled studies in humans, and the benefits from the use of the drug in pregnant women may be
acceptable despite its potential risks
Or
There are no animal reproduction studies and no adequate and well- controlled studies in humans
D There is positive evidence of human fetal risk based on adverse reaction data from investigational or
marketing experience or studies in humans, but the potential benefits from the use of the drug in pregnant
women may be acceptable despite its potential risks
X Studies in animals or humans have demonstrated fetal abnormalities or if there is positive evidence of fetal
risk based on adverse reaction reports from investigational or marketing experience, or both, and the risk
of the use of the drug in a pregnant woman clearly outweighs any possible benefit
815Management of inflammatory bowel disease in pregnancydrugs IBD did not a significantly increase the risk of
congenital abnormalities (OR 1.16), stillbirth (OR 2.38),
spontaneous abortion (OR 1.14), preterm delivery (OR 1.35)
or low birth weight (OR 0.93).64
Sulfasalazine therapy should be accompanied by extra
folate supplementation, as this medication halts folateTable 2 Drug treatment for IBD and risks during pregnancy.72
Drug class FDA
category
ECCO rating Clin
Aminosalicylates B Safe No i
Com
C Dibu
Incr
asso
Metronidazole B Probably safe No b
1 po
expo
rate
Quinolones C Probably safe Mus
not
Shou
risk
Anti-TNF B Probably safe No t
the
Natalizumab C Safe
avai
Corticosteroids C Safe Use
clef
Incr
Cyclosporine C Probably safe Doe
Azathioprine D Safe Can
Methotrexate X Contraindicated Con
Disc
Thalidomide & lenalidomide X Contraidindicated Consynthesis by inhibiting dihydrofolate reductase. Folic acid
supplementation was shown to decrease the augmented risk
of oral clefts and cardiovascular anomalies associated with
folate antagonist treatment during pregnancy.65 Caution
should be applied regarding the use of some mesalamine
formalations (e;g. asacol) which contain dibutyl phthalateical recommendations
ncreased risk
bine sulfasalazine with folate supplements
tyl phthalate-coated mesalamine formulations
eased risk of malformations in the male urogenital tract
ciated with DBP.
irth defects
pulation-based case-control study found that infants of women
sed to Metro in 2nd to 3rd months of pregnancy had higher
s of cleft lip with or without cleft palate
culoskeletal abnormalities in animal studies, human data do
show increased abortion or congenital malformation rates.
ld be avoided in the first trimester due to potential increased
of arthropathy
ransfer to the embryo/fetus in first trimester. Can be used in
first two trimesters of pregnancy and during lactation.
ty during pregnancy and lactation still unknown. Limited data
lable
during the first trimester associated with increased risk of oral
t in the newborn
eased risk of adrenal insufficiency
s not appear to be a major teratogen
be continued to maintain remission during pregnancy.
traindicated in pregnancy.
ontinue 3–6 months before conception.
traindicated in pregnancy.
816 S. Vermeire et al.(DBP) as a coating agent. Use of DBP-coated medications
produces measurable phthalate metabolite levels in urine.
Prenatal exposure to DBP can cause congenital malforma-
tions in the male urogenital tract.66
The sulfasalazine metabolite sulfapyridine is secreted
into breast milk. Aminosalicylates are generally considered
safe during lactation, although a case of bloody diarrhea in
an infant has been reported.67–69
5.2. Antibiotics
5.2.1. Metronidazole
Metronidazole is considered a low risk drug during pregnancy
(FDA class B, Table 2). Several studies did not find an
association between metronidazole treatment and birth
defects,70 but one population-based case–control study
observed an increased incidence of cleft lip and/or cleft
palate in infants of mothers exposed to metronidazole in the
first trimester of pregnancy.71 Metronidazole use in preg-
nant IBD patients is best limited to short-term use for the
treatment of pouchitis. Metronidazole is excreted in breast
milk and breastfeeding during metronidazole use is not
recommended.70
5.2.2. Quinolones
Quinolone antibiotics are FDA category C drugs and should be
avoided because they carry an increased risk of arthropathy
due to their high affinity for bone and cartilage.
Musculoskeletal abnormalities have been observed after
exposure to quinolones during pregnancy in animal studies,
but human studies do not show an increased risk of
spontaneous abortion or congenital malformations. Although
the overall risk is considered limited, ECCO recommends to
avoid quinolone use in the first trimester of pregnancy.72
Data on breastfeeding are limited, but quinolone use is
probably compatible with breastfeeding.73,74
5.3. Biologics
5.3.1. Anti-TNF therapies
The recent London position statement on biological therapy
for IBD states that anti-tumor necrosis factor (TNF) therapy
is considered low risk and can be used in the preconception
period and during the first two trimesters of pregnancy.14 A
2009 survey among French gastroenterologists revealed that
only 35.1% discontinued anti-TNF therapy at the time of
conception.75
The cytokine TNF-α not only plays a pivotal role in the
inflammation process underlying IBD, but also plays physio-
logical roles in host defense mechanisms and pregnancy.
Expression of TNF-α and its receptors is found in the uterus,
placenta and the embryo, but knocking out expression of
TNF-a in mice does not affect pup morphology, growth or
litter size in mice.76 During pregnancy, TNF-α probably plays
a role in protecting the fetus against teratogenic stress,
since exposure to the teratogen cyclophosphamide induced
significantly more malformations in fetuses of TNF-α
knockout mice than in wildtypes.77
Despite the role of TNF in pregnancy, treatment with
anti-TNF antibodies can be considered safe in the precon-
ception period and the first part of pregnancy, because IgGantibodies do not cross the placenta in the first pregnancy
trimester, and transplacental IgG transport mainly takes
place during the late second and third trimester of
pregnancy.78,79 Maternal transfer of IgG during the last
trimester of pregnancy provides the neonate with sufficient
acquired immunity to defend itself while its own immune
system is becoming fully functional. Other types of immu-
noglobulins do not cross the placenta.
IgG is actively transported across the placenta via an active
transport mechanism consisting of pH-dependent binding of
immunoglobulins by fetal Fc receptors. Fc receptors on the
membrane of syncytiotrophoblast cells capture immunoglob-
ulins from the maternal circulation, bind them in a pH-
dependentmanner during transcytosis and release them in the
fetal circulation.80–82 Neonatal Fc receptors have different
binding affinities for the different IgG subclasses, with the
most efficient transplacental transport for IgG1 and least
efficient for the IgG2 subclass.79,83
The currently available TNF inhibitors (etanercept,
infliximab, adalimumab, golimumab and certolizumab) are
all classified as FDA category B drugs, indicating that no
teratogenic effects of these drugs were observed in animal
reproduction studies, but adequate and controlled human
safety data are still lacking. All current TNF inhibitors with
exception of certolizumab are of the IgG1 isotype and
contain an Fc fragment, implicating they will be transported
to the fetus according to the active transport mechanism
described earlier. Certolizumab is a pegylated Fab’ frag-
ment of an anti-TNF monoclonal antibody without Fc
fragment and would theoretically be expected not to cross
the placenta, although human data on this topic are still
lacking.84
Review of the FDA drug surveillance database prompted
concern that anti-TNF treatment might be associated with
the so-called VACTERL syndrome, characterized by multiple
birth defects: Vertebral, Anal atresia, Cardiac abnormali-
ties, Tracheoesophageal fistula, Esophageal atresia, Renal
abnormalities and Limb abnormalities.85 However, none of
the reported cases showed 3 of these anomalies, necessary
for formal VACTERL diagnosis and several methodological
criticisms to this study cast a doubt on the assumption that
anti-TNF treatment carries and increased risk for birth
defects of the VACTERL type.86,87
Several animal studies concerning the development of
the immune system after exposition to anti TNF antibodies in
utero have been published. Mice exposed to anti TNF
antibodies in utero or at birth have growth retardation as
well as a marked atrophy of the thymus, spleen and lymph
nodes as well as a decreased expansion of B cells.88,89 On the
other hand, injection of golimumab in pregnant macaques
does not affect the development and maturation of the
immune system of the offspring, although golimumab levels
remained detectable in offspring up to 6 months after
birth.89
Transfer of anti-TNF antibodies to the fetus during the
last part of pregnancy may mean exposure of the neonate in
the first months after birth, raising potential concerns about
infection and response to vaccines.14 The immunosuppres-
sive effect of maternal treatment with TNF inhibitors during
pregnancy on their infants is sadly illustrated by a fatal case
of disseminated BCG infection after BCG vaccination in an
infant born to a mother treated with infliximab throughout
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during pregnancy probably should be considered to be
immunocompromised, as their mothers are. ECCO guidelines
state that live vaccinations (BCG, rotavirus, mumps-
measles-rubella (MMR) and varicella zoster) are contra-
indicated until exposure to immunosuppressants has been
discontinued for at least 3 months.91 In view of the long half-
life of TNF inhibitors in newborns,89 further studies are
required to determine whether this safety period is
sufficient. Since spreading of vaccine virus to household
contacts has been described after oral poliomyelitis and
rotavirus vaccination, these vaccinations are therefore
contraindicated in household contacts of immunocompro-
mised individuals. Non-live vaccines can safely be given to
immunocompromised individuals and mostly lead to an
adequate humoral immune response.92
IgA is the predominant immunoglobulin in human milk, so
secretion of TNF inhibitors in milk is likely to be very limited
and breastfeeding under anti-TNF treatment can be consid-
ered safe.84
5.3.1.1. Infliximab. Accumulating clinical data indicate
that infliximab use is safe in the preconception period and
during at least the first two trimesters of pregnancy14
The TREAT registry describes 36 pregnancies in patients
exposed to infliximab. No fetal malformations were ob-
served, and rates of miscarriage (11.1 vs. 7.1%) and neonatal
complications (8.3 vs 7.1%) were comparable between
infliximab-treated patients and non-exposed patients.93
The Infliximab safety database collected data on 96
pregnancies with infliximab exposure between 3 months
before conception to the end of the first trimester of
pregnancy, with rates of miscarriage and fetal complications
comparable to those expected for the general population.94
A recent observational study by Schnitzler et al. studying
pregnancy outcomes of 42 pregnancies exposed to anti-TNF
treatment (35 with infliximab treatment, 7 with adalimu-
mab treatment) observed that pregnancy outcomes in
exposed pregnancies were not different from those in
pregnancies occurring before anti-TNF treatment or with
anti-TNF treatment before but not during pregnancy, but
worse than outcomes of pregnancies before diagnosis of
IBD.95
An important indication that the benefit of infliximab
treatment to achieve or maintain remission of disease during
pregnancy may outweigh the potential risks is a case series
of CD patients intentionally treated with infliximab during
pregnancy described by Mahadevan et al. in 2005. In a series
of 10 CD patients treated with infliximab during pregnancy,
8 patients received infliximab throughout pregnancy, one
patient was started on infliximab in the third trimester for a
severe flare, and one received infliximab treatment in the
first trimester of pregnancy. All 10 pregnancies ended in live
births of children without congenital malformations or
intrauterine growth retardation. Three births occurred
before 37 weeks and one infant had low birth weight.96
A number of case reports indicate that placental transfer
of infliximab leads to prolonged exposure of the neonate:
serum levels in neonates often surpassed these in maternal
serum and remained detectable up to 6 months after
birth.97,98 Immaturity of the reticuloendothelial system
leading to slow antibody clearance is probably responsiblefor this effect. Discontinuing infliximab at the end of the
second pregnancy trimester or early in the third trimester
may help to reduce infliximab exposure in the newborn.14,99
Kane et al. reported that infliximab levels in newborn
infants were undetectable when infliximab treatment had
been stopped around gestational week 30.99
Infliximab could not be detected in breast milk,99–101 so
infliximab treatment is considered to be compatible with
breastfeeding.99
5.3.1.2. Adalimumab. Although clinical data are scarce up
to now, adalimumab is also considered low risk during
preconception and in at least the first two trimesters of
pregnancy.14
Adalimumab has received an FDA category B label. It is a
fully humanized antibody of the IgG1 isotype. The mecha-
nism and rate of transplacental transfer are comparable to
those of infliximab. A recent study has shown that infants
born to mothers who have received adalimumab up to
56 days before delivery have therapeutic levels of adalimu-
mab in cord blood and in serum up to 7 weeks after birth.98
A limited number of case reports in which adalimumab
use during pregnancy is followed by the birth of a healthy
child have been published to date.14,102
High levels of anti-TNF in the newborn who have been
exposed in utero, are present at a crucial period for the
development of the immune system. An ongoing study in the
USA is assessing the development and the risk of infection in
children who have received anti TNF and/or thiopurines in
utero. Preliminary results of this study have been presented
at the Digestive Diseases Week in 2010. These results are
reassuring, in that they do not show any obvious adverse
signal. Definitive results are awaited. More data are needed
to study the immune status of children who have been
exposed to anti TNF in utero.
5.3.1.3. Certolizumab pegol. Certolizumab is a pegylated
Fab′ fragment of an anti-TNF monoclonal antibody without
Fc fragment. Certolizumab would therefore be expected not
to be transferred across the placental barrier according to
the mechanism described above. Animal studies indeed
report much lower placental transfer of pegylated Fab′
antibodies; data in humans are not yet available, but a case
of certolizumab administration as rescue therapy in the third
pregnancy trimester of an IBD patient had a favorable
outcome.102–104 However, it is possible that the small Fab′
fragment could cross the placenta passively after cleaving
off the PEG-tail. The recent London position statement
considers certolizumab pegol to be low risk prior to
conception and during pregnancy. Certolizumab is compat-
ible with breastfeeding.79
5.3.2. Natalizumab
Natalizumab is an α-4 integrin inhibitor approved for
treatment of CD in the US, but not in Europe. It is a
humanized antibody of the IgG4 isotype, which is actively
transported over the placenta in the second and third
trimester of pregnancy, but less efficiently than IgG1
antibodies.70 Experience with natalizumab in the context
of IBD is still limited, but this biological is widely used for
treating multiple sclerosis. It has received an FDA category C
label. A series of 164 pregnancies exposed to natalizumab
818 S. Vermeire et al.during the first trimester of pregnancy revealed no adverse
outcomes.79 Recent case reports likewise described no
apparent negative effects of natalizumab use,14 but a case
series of 35 women revealed one child born with hexadac-
tyly.105,106 Data on the use of natalizumab during lactation
are lacking at this time. So at present insufficient data is
available to reach a definite conclusion on the safety of
natalizumab during pregnancy and lactation.
5.4. Corticosteroids
Corticosteroids are FDA category C drugs. They are believed
to be safe throughout pregnancy at doses up to 15 mg per
day.14 Higher doses increase the risk of infection and
premature delivery.107 Systemic treatment with corticoste-
roids during the first trimester of pregnancy was found to
slightly augment the incidence of oral clefts, from 1 per 1000
live births to 1.3–3.3 per 1000 live births (OR 3.35, 95% CI
1.97–5.69). The overall risk of congenital malformations,
however, is not significantly increased (OR 1.45, 95% CI
0.80–2.60).108
Pregnant women are preferably treated with prednisone
or prednisolone, as the bulk of these compounds is inac-
tivated by placental 11β-hydroxy steroid dehydrogenase,
the physiological mechanism in place to protect the fetus
from elevated maternal cortisol levels during pregnancy. For
treatment of the fetus, dexamethasone or betamethasone are
the steroids of choice, as they cross the placental barrier more
efficiently.109
While the safety of inhaled or intranasal budenoside (FDA
category B) in pregnancy has been extensively demonstrat-
ed,110 no safety data are available on oral budenoside. No
adverse pregnancy outcomes were observed in a limited case
series covering 8 patients treated with oral budenoside during
pregnancy.111
Treatment with corticosteroids is compatible with breast-
feeding.112,113 Less than 0.1% of the maternal dose of pred-
nisolone is secreted into milk, corresponding to less than 10%
of the infants endogenous cortisol level.68
5.5. Cyclosporine
Cyclosporine crosses the placenta but is rapidly cleared in
the neonate and has no known teratogenic effects. FDA
categorizes cyclosporine in pregnancy category C for lack of
controlled studies in humans (Table 2), but cyclosporine
does not appear to be a major teratogen. Extensive
experience exists with use of cyclosporine in pregnancy,
mainly in transplant patients.67 A meta-analysis including 15
studies on the use of cyclosporine in pregnancy, showed that
cyclosporine use in pregnancy was not associated with major
malformations, but tended to decrease birth weight and
duration of gestation, although these effects did not reach
statistical significance.73 In the context of IBD, cyclosporine
use in refractory UC during pregnancy has been shown to be
safe and effective. Its main use in pregnant IBD patients is
the prevention of urgent colectomy in fulminant UC.114,115
Although a number of cases are reported where no overt
adverse effects were observed in breastfed infants of mothers
treated with cyclosporine, the use of this drug during lactation
is generally not advised, as cyclosporine is secreted in milk athigh concentrations, leading to potential nephrotoxicity and
immunosuppression in exposed infants.116
5.6. Thiopurines
Azathioprine and 6-mercaptopurine are still designated as
FDA category D drugs (Table 1), indicating that increased
risk for the fetus exists, but the risk must be weighed against
the possible benefits of the drug.
The FDA category D ratingwas originally given because in the
1960s teratogenic effects of azathioprinewere observed inmice
and rabbits after intraperitoneal administration at high doses,
related to its use as cytostatic agent. Although skeletal and
visceral malformations in rabbits and mice have also been
observed with oral doses equivalent to the human dose,
multiple case series and cohort studies in human pregnancy,
mostly in transplant recipients and IBD patients, have not
revealed increased incidence of congenital anomalies or
recurrent patterns of congenital anomalies,117 which is why
currently almost 9 out of 10 experts continue azathioprine
throughout pregnancy118).
A recent Danish cohort study, showed an increased risk
of preterm delivery and low birth weight in women exposed
to azathioprine or 6-mercaptopurine during pregnancy, but
no significant increase in congenital malformations. Compa-
ring the outcomes of 76 patients exposed to thiopurines
during pregnancy to those in a cohort of pregnant women
treated with azathioprine or 6-mercaptopurine before but
not during pregnancy, showed that adverse birth outcomes
in exposed pregnancies mainly depended upon the under-
lying disease state, rather than the drug exposure.26,60,119–122
In the CESAME study, a cohort study comparing IBD patients
exposed to thiopurine therapy during pregnancy with wo-
men receiving other treatments or women without any drug
therapy, thiopurine therapy did not significantly increase
the incidence of prematurity, low birth weight, or congenital
abnormalities.123
Preliminary results from the PIANO study suggested a
potential influence of thiopurines on postnatal development,
as the percentage of developmental milestones reached by
infants of mothers treated with thiopurines at 9 months was
lower than in infants of untreated mothers or mothers treated
with biologics (Mahadevan et al. DCC 2010 — Abstract #764).
Thiopurines undergo a complex metabolization process
and the placenta forms a partial barrier to their metabolites,
as the active metabolites 6-thioguaninenucleotides (6-TGN)
are detectable in fetal red blood cells, whereas 6-
methylmercaptopurine (6-MMP) is not.124 Thiopurine me-
tabolites may cause myelosuppression in mother and child.
To avoid excessively high levels, dosing of 6-TGN at least
once during pregnancy is recommended.125 Thiopurine
treatment is generally considered a contraindication for
breastfeeding, but Christensen et al. demonstrated low 6-MP
levels in breast milk and conclude that breastfeeding during
treatment with azathioprine seems safe, with exposure of a
breastfed infant estimated at b1% of the maternal dose
(b0.008 mg 6-MP/kg). Since the majority of thiopurine
metabolites are excreted in milk in the first 4 h after intake
of the drug, they recommend reducing the infant's exposure
to the drug by allowing a 4-hour time interval between
thiopurine intake and breastfeeding or else discarding the
first portion of the milk.125
Table 3 General recommendations on pregnancy in IBD
patients.
Before conception
Achieve disease remission
Discuss necessity of drugs to maintain disease remission
Check and treat nutritional deficiencies (Folate, B12, Iron,
Vitamin D)
Folic acid in all in anticipation of a pregnancy
During pregnancy
Monitor patient 8–12 weeks (lab tests when AZA or anti-TNF)
Stop anti-TNF if possible around week 20–22
Discuss way of delivery: C-section in perianal CD or IPAA pouch
Treat flares with IV steroids and anti-TNF
Preferentially use amoxicilline clavulanic acid if complications
necessitate the use of antitbiotics
After delivery
Discuss with patient if and when drugs should be restarted
Be careful for flare in weeks following delivery
Discuss breastfeeding
Notify pediatrician of in utero exposure to TNF inhibitors and
discuss implications for vaccination of the newborn
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Methotrexate (MTX) has teratogenic properties and is
contraindicated during pregnancy (FDA category X —
Table 1). Since MTX is widely distributed and its metabolites
have long tissue half-lives,126–128 MTX administration must
be stopped 3 to 6 months before conception.129 Exposure to
MTX in the first trimester of pregnancy is associated with the
aminopterin syndrome, a combination of growth deficiency
with major central nervous system, bone and cardiac
abnormalities.70,107 It is recommended to provide folic acid
supplementation after MTX withdrawal, as MTX acts as a
folate antagonist. MTX is excreted into breast milk at low
concentrations,130 but is contraindicated during lactation
because of its potential accumulation in the child's tissues.
The effect of MTX on spermatogenesis and male fertility
remains somewhat controversial, as some studies report
reversible oligospermia under MTX treatment. No increase of
congenital abnormalities in children conceived by fathers on
MTX have been reported. A cautious course of action would
be to wait 3 months before conception after withdrawal of
MTX.67
5.8. Thalidomide and lenalidomide
Thalidomide and its analogue lenalidomide partly counter-
act the effects of TNF-α and have been used in patients with
refractory Crohn's disease, although currently available
systematic evidence does not clearly demonstrate the
benefit of these drugs.131 In view of its well-documented
teratogenicity, including limb defects, central nervous
system defects and congenital abnormalities in the cardio-
vascular, respiratory, gastrointestinal and genitourinary
tract, thalidomide is absolutely contraindicated in pregnan-
cy (FDA category X). Patients taking thalidomide are advised
to use two complementary contraceptive methods.132,133
Although lenalidomide appears less teratogenic in animal
studies, exhibiting only teratogenic properties in rabbits at
doses with maternal toxicity,73 its structural analogy with
thalidomide and the lack of studies demonstrating its safety,
are absolute contraindications for using this drug in pregnant
patients or patients wishing to become pregnant.
6. In summary
General recommendations for treating IBD patients before and
during pregnancy and after delivery are summarized in Table 3.
IBD patients have normal fertility, except for women after IPAA
and men under sulfasalazine treatment. It is of the utmost
importance to try and achieve disease remission prior to
conception, as patients with quiescent disease can expect
normal pregnancy outcomes, whereas active disease carries an
increased risk of preterm delivery and low birth weight. Babies
born to mothers with ulcerative colitis may have a limited
increased risk of congenital malformations.
Clinicians should discuss the need for drug therapy to
maintain remission with their patients in order to ensure
therapy compliance. Most IBD drugs are compatible with
pregnancy, except for methotrexate and thalidomide. If
possible, anti-TNF therapy should be stopped by the end of
the second trimester and the choice of delivery route shouldbe discussed with the patient. Cesarean section is indicated
in case of active perianal disease and if obstetrical
difficulties are expected in patients with an IPAA pouch.
After delivery women who wish to breastfeed their children
should be placed on lactation compatible treatments.6.1. Practical aspects and personal recommendations
6.1.1. Medical treatment recommendations
We always advocate patients to avoid pregnancy when the
disease is active or unstable. In case of longstanding stable
inactive disease, we try to discontinue any treatment during
pregnancy. If not we discuss on a case by case basis the
benefit/risk of treatment. We usually advocate patients to
continue purine analogues or mesalazine. Patients under
anti-TNF therapy will continue until week 20 when the anti-
TNF will be stopped for the remaining of the pregnancy.6.1.2. Treatment of disease flare during pregnancy
When a disease flare occurs during pregnancy, the approach
taken depends on the duration of the pregnancy and on the
previous therapy of that patient before pregnancy. When
the flare occurs in the last weeks of pregnancy, the option of
delivery, hence avoiding medication exposure to the baby,
is preferred. This option is of course not possible when the
flare occurs in the first or second trimester. In the latter
scenario, IV steroids or anti-TNF therapy are good options
and both are discussed with the patients. Women should be
made aware of the placental transfer of anti-TNF from week
20–22 onwards, as this has implications on the vaccination
of the baby (BCG and Rotavirus in particular). This should
also be communicated to the pediatrician in charge of the
baby.
820 S. Vermeire et al.When a serious complication occurs where antibiotics are
needed (abcess…), quinolones will be avoided and we prefer
using drugs as amoxicilline-clavulanic acid instead.
6.1.3. Obstetric care for the pregnant IBD patient
We do not feel all patients with IBD should be referred to
high risk pregnancy clinics. Patients whom we do refer for
specialized obstetrics care are pregnant patients with active
IBD necessitating steroid and/or anti-TNF treatment, pa-
tients with ileostomies and patients with ileoanal pouches.
We do not have joint gastroenterology-obstetric clinics, but
there are staff members in our department of obstetrics
dedicated for high-risk pregnancies. Patients with IPAA
surgery in the past will always be advised to undergo
caesarian section, and our abdominal surgeon will be
present during the delivery.Acknowledgements
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